chart

The S&P Health Care sector was down 11.4% last week, and the S&P Biotechnology sector fared even worse, losing 13%. The RS analysis is still positive on both, however, and the breakout above the multi-year base formations still looks significant. The current decline could go further, but both sectors are still expected to perform better than the S&P.